VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
BiTAC-ADC is a bispecific antibody-drug conjugate that enables tumor-restricted activation, potentially reducing systemic toxicity. BiTAC-TCE is a bispecific T cell engager designed for enhanced tumor killing. Both platforms leverage VERAXA’s expertise in antibody engineering, built on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL).
The company’s presentation at BIO comes amid growing interest in next-generation cancer therapies that improve efficacy and safety. VERAXA’s platforms address key limitations of conventional ADCs and T cell engagers, such as off-target effects and limited solid tumor penetration.
For more details, the full press release is available at https://ibn.fm/r8zEz. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA.
VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on these statements, which are based on information available as of the date hereof. The company undertakes no duty to update this information unless required by law.
